Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
NCT ID: NCT07168902
Last Updated: 2025-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
228 participants
INTERVENTIONAL
2025-10-24
2026-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BL1107 Low dose
BL1107 Low dose
Dosed twice daily for 28 days.
BL1107 High dose
BL1107 High dose
Dosed twice daily for 28 days.
Timolol maleate 0.5%
Timolol maleate 0.5%
Dosed twice daily for 28 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BL1107 Low dose
Dosed twice daily for 28 days.
BL1107 High dose
Dosed twice daily for 28 days.
Timolol maleate 0.5%
Dosed twice daily for 28 days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Any active ocular disease
* Anticipated wearing of contact lenses during study
* Contraindication to pupil dilation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bausch & Lomb Incorporated
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Global Research Management, Inc.
Glendale, California, United States
Eye Research Foundation
Newport Beach, California, United States
Levenson Eye Associates
Jacksonville, Florida, United States
Central Florida Eye Associates
Lakeland, Florida, United States
Lee Shettle Eye and Hearing
Largo, Florida, United States
Andover Eye Associates
Andover, Massachusetts, United States
Scott & Christie and Associates, PC
Cranberry Township, Pennsylvania, United States
Total Eye Care, P.A.
Memphis, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RX01-BL1107-1201
Identifier Type: -
Identifier Source: org_study_id